Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Cartilage Repair Scaffold at the 2019 International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting
BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 5, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase HYALOFAST, a
View HTML
Toggle Summary Anika to Showcase Regenerative Medicine and Orthobiologics Portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress
BEDFORD, Mass. --(BUSINESS WIRE)--May 13, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its regenerative
View HTML
Toggle Summary Anika to Participate in Two Investor Events in May 2019
BEDFORD, Mass. --(BUSINESS WIRE)--May 6, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that the Company will participate in
View HTML
Toggle Summary Anika Reports First Quarter 2019 Financial Results
Total Revenue Increased 16% Year-over-Year Solid Bottom Line Performance with $0.31 Diluted EPS New Leadership Added to Accelerate Innovation and Expand Commercial Reach Announces $50 Million Share Repurchase Program BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Anika Therapeutics, Inc.
View HTML
Toggle Summary Anika Announces $50 Million Share Repurchase Program
BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that its Board of Directors has
View HTML
Toggle Summary Anika Appoints Stephen Goldy as Vice President of U.S. Sales
Seasoned commercial leader to oversee hybrid commercial organization and upcoming launch of Bone Repair Surgical Therapy in the U.S. BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company
View HTML
Toggle Summary Anika to Issue First-Quarter 2019 Financial Results and Business Highlights on Thursday, May 2
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2019 financial results after the close of the market on Thursday, May 2, 2019 and hold its investor conference call on the same day, Thursday,
View HTML
Toggle Summary Anika to Highlight Regenerative Medicine and Orthobiologics Portfolio at 2019 Asia Pacific Orthopaedic Association Sports Meeting
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its regenerative
View HTML
Toggle Summary Anika Appoints Robert Richard, Ph.D. as Vice President of Research and Development
Industry veteran brings extensive experience leading high-performing R&D groups BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
View HTML
Toggle Summary Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting
BEDFORD, Mass. --(BUSINESS WIRE)--Mar. 11, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its innovative
View HTML